Cormac Owens

Risk stratification of high‐risk metastatic neuroblastoma: A report from the HR‐NBL‐1/SIOPEN study

Ruth Ladenstein, Gudrun Schleiermacher, Ulrike Pötschger, 2018, Pediatric blood & cancer.

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.

Ruth Ladenstein, Henrik Schroeder, Ulrike Pötschger, 2018, The Lancet. Oncology.